Curi Bio
Seattle
About Curi Bio
Curi Bio is a biotechnology company that focuses on advancing drug discovery and development through innovative approaches involving human stem cells, systems biology, and data analytics. The company's primary goal is to accelerate the process of identifying and developing new medicines. Curi Bio's platform revolves around the use of human stem cells, which have the potential to be differentiated into various cell types, replicating the behavior of different tissues and organs. This allows researchers to create more accurate and relevant models for studying disease mechanisms and testing potential drug candidates. NanoSurface Biomedical Is Now Curi Bio.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $30.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2025)
- Website: curibio.com
- Phone: +1 (800) 913-4403
Industries & Categories
Artificial Intelligence (AI), Biopharma, Biotechnology, Medical, Service Industry
Social Profiles
Canonical: https://fsome.com/organization/curi-bio-48338 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.